Abstract
Antiparkinsonian activity of amantadine was first described in 1969 and was confirmed by several trials in later years. The improvement of parkinsonian symptoms is mild. However, in patients with motor fluctuations, clear reduction of dyskinesia could be observed. A possible neuroprotective impact is still under discussion, but lacking evidence. The clinical efficacy is caused by two main mechanisms of action. First, amantadine shows direct and indirect modulation of the dopaminergic system. Moreover, amantadine inhibits N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Preclinical data suggest an association of both neuroprotective potential and antidyskinetic properties with the antiglutamatergic activity of amantadine. In recent years, the antidyskinetic efficacy generated increasing interest and subsequent development of new (immediate and extended release) amantadine formulations.
Similar content being viewed by others
References
Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14:5135–51.
Bailey EV, Stone TW. The mechanism of action of amantadine in parkinsonism: a review. Arch Int Pharmacodyn Ther. 1975;216:246–62.
Crosby NI, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003a;1:CD003468.
Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst Rev. 2003b;2:CD003467.
Davies WL, Grunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE. Antiviral activity of 1-adamantanamine (amantadine). Science. 1964;144:862–3.
Evidente VG, Adler CH, Caviness JN, et al. A pilot study on the motor effects of rimantadine in Parkinson’s disease. Clin Neuropharmacol. 1999;22:30–2.
Greenamyre IT, O’Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol. 1991;48:977–81.
Group PS. The glutamate antagonist remacide improves motor performance in levodopa-treated Parkinson’s disease. Neurology. 1999;52(Suppl 2):A262.
Jörg I, Ringendahl H, Ischebeck W, Steube D, Lambert-Baumann I. Amantadinsufat-Infusion zur Behandlung von Vigilanz- und Antriebsstörungen. Nervenheilkunde. 2000;19:512–28.
Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol. 1986;43:126–7.
Kornhuber J, Bormann I, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel. Eur J Pharmacol. 1991;206:297–300.
Kulisevsky I, Tolosa E. Amantadine in Parkinson’s disease. In: Koller WC, Paulsen G, editors. Therapy in Parkinson’s disease. New York: Marcel Dekker; 1987. p. 309–16.
Malkani R, Zadikoff C, Melen O, et al. Amantadine for freezing of gait in patients with Parkinson’s disease. Clin Neuropharmacol. 2012;35(6):266–8.
Müller T. Medikamentöse Therapie des Morbus Parkinson. Bremen: UNI-MED-Verlag; 2015.
Müller T, Kuhn W, Schulte T, Przuntek H. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neurosci Lett. 2003;339(1):25–8.
Nastuk WC, Pu PC, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature. 1976;264:76–9.
Obeso JA, Martinez-Lage IM. Anticholinergics and amantadine. In: Koller WC, Paulsen G, editors. Handbook of Parkinson’s disease. New York: Marcel Dekker; 1987. p. 309–16.
Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine) extended release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID study). A randomized clinical trial. JAMA Neurol. 2017;74:941–9.
Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol. 1996;39:574–8.
Quack G. Amantadin reduziert L-Dopa-induzierte motorische Fluktuationen – präklinische und klinische Ergebnisse. Aktuelle Neurol. 1998;25:258–60.
Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson’s disease. Dis Nerv Syst. 1977;38:605–8.
Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168–70.
Schwab RS, Poskanzer DC, England AC, Young RR. Amantadine in Parkinson’s disease: review of more than two years’ experience. JAMA. 1972;222:792–5.
Shannon KM, et al. Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol. 1987;10:522–6.
Thomas A, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–3.
Uitti RJ, Rajput AK, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology. 1996;46:1551–6.
Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson’s disease in cross-sectional study. Ann Neurol. 2010;68:963–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 This is a U.S. Government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this entry
Cite this entry
Kuhn, W., Müller, T. (2020). Amantadine for Treating Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_220-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_220-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine